Enforcement Report - Week of April 10, 2024
BETHLEHEM, Pa., Feb. 13, 2024 /PRNewswire/ -- B. Braun Medical Inc. (B. Braun), a leader in smart infusion therapy and pain management, announced today the launch of its new Heparin Sodium 2,000 units in 0.9% Sodium Chloride Injection, 1,000 mL (2 units/mL), the fifth product in its portfolio of Heparin premixed bags.
B. Braun's Generic Calcium Gluconate Receives Approval in the U.S.
Enforcement Report - Week of May 24, 2023
Health Canda Issues Recall of B. Braun Medical`s Heparin sodium in 5% Dextrose injection
Enforcement Report - Week of March 15, 2023
Enforcement Report - Week of March 1, 2023
Enforcement Report - Week of December 14, 2022
LUGANO, Switzerland--(BUSINESS WIRE)--Healiva®, a patient-centric company delivering life-enhancing precision medicine for patients with chronic and acute wounds, announced today the acquisition of critical manufacturing assets from B. Braun Medical AG Switzerland, an affiliate of German medical and pharmaceutical device company, B. Braun SE. The acquisition includes a qualified cell bank, which is essential for the GMP-compliant manufacturing of Healiva’s first cell therapy product, EpiDex®: an autologous epidermis derived from the patient’s own hair cells. Financial details have not been disclosed.
Enforcement Report - Week of March 23, 2022